Real-world first-line treatment with pembrolizumab for non-small cell lung carcinoma with high PD-L1 expression: Updated analysis.

Yasuyuki IkezawaRyo MoritaHidenori MizugakiKazunari TateishiKeiki YokooToshiyuki SumiHajime KikuchiYasuo KitamuraAtsushi NakamuraMaki KobayashiMari AsoNozomu KimuraFumiaki YoshiikeFuruta MegumiHisashi TanakaMotoki SekikawaTsutomu HachiyaKeiichi NakamuraFumihiro HommuraNoriaki SukohKenichiro ItoTakashi KikuchiToshihiko AgatsumaHiroshi Yokouchi

Published in: Cancer medicine (2024)

COMB may be effective as a first-line treatment for NSCLC with high PD-L1 expression in a selected subset of patients.

Keyphrases

end stage renal disease
small cell lung cancer
ejection fraction
chronic kidney disease
newly diagnosed
advanced non small cell lung cancer
prognostic factors
stem cells
cell therapy
patient reported outcomes
mesenchymal stem cells
patient reported
data analysis